NeOnc' Phase 2 Data Could Put Cancer on the Ropes

The article states that NeOnc Technologies Holdings (NASDAQ: NTHI) has answered its “Phase 2a question,” but provides no clinical data, efficacy endpoints, safety results, regulatory updates, or financial details. The limited disclosure prevents a meaningful assessment of the trial’s implications for the company or its shares.